AD________________

GRANT NUMBER DAMD17-94-J-4170

TITLE: Regulation of Membrane Protease Associated with Breast Cancer

PRINCIPAL INVESTIGATOR: Leslie Goldstein, Ph.D.

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20057

REPORT DATE: August 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19961125 069

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 1996	Annual (1 Aug 95 - 31 Jul 96)

4. TITLE AND SUBTITLE
Regulation of Membrane Protease Associated with Breast Cancer

5. FUNDING NUMBERS
DAMD17-94-J-4170

6. AUTHOR(S)
Leslie Goldstein, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Georgetown University
Washington, DC 20057

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 2170-25012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200*
mp170 seprase is a homodimeric 170 kDa membrane-bound gelatinase whose expression correlates with the invasiveness of the human melanoma cell line LOX. We have isolated a cDNA clone, pA15, that encodes its 97 kDa subunit. COS-7 cells transfected with pA15 express a 170 kDa gelatinase which is recognized by mAbs directed against mp170 seprase. The deduced amino acid sequence predicts a type II integral membrane protein of 760 amino acids. And its carboxyl terminus contains a putative catalytic region which is homologous to the nonclassical serine protease subfamily represented by the ectopeptidase Dipeptidyl Peptidase IV (DPPIV). However, mp170 seprase exhibits its highest identity(94%) with the integral membrane protein Fibroblast Activation Protein Alpha (FAP) that is expressed in vivo in carcinomas and sarcomas but whose function is unknown. Unlike FAP, we have isolated cDNA clones that encode mp170 seprase in the human breast carcinoma cell line MDA-MB-436. Preliminary sequence analysis confirms the sequence obtained for LOX mp170 seprase.

14. SUBJECT TERMS
Breast Cancer, melanoma, protease, mp170, seprase, cDNA, FAP, DPPIV.

15. NUMBER OF PAGES
15

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

NSN 7540-01-280-5500

DTIC QUALITY INSPECTED 3

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

L.G. In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

L.G. In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

L.G. In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Leslie Goldstein 8/29/96

PI - Signature / Date

TABLE OF CONTENTS

Page	
1	Cover Page
2	SF 298
3	Foreword
4	Table of Contents
5- 6	Introduction
7- 9	Body
10	Conclusions
11- 12	References
13- 15	Appendix
13	Figure Legends
14	Figure 1
15	Figure 2

INTRODUCTION

Background

One of the fundamental requirements for the metastatic behavior of cancer is the ability of tumor cells to invade the extracellular matrix (ECM). This capability allows for the subsequent dissemination of tumor cells to secondary sites in the body via the circulation and lymphatics (1,2). Indeed, in advanced breast cancer metastases to the lung, liver, lymphatic organs and bone etc. are common. And it is well established that a variety of secreted proteases of the serine(3,4), cysteine(5,6), metalloproteinase(7,8,9) and aspartic acid (10,11) classes which can also be localized to the cell membrane (12,13,14) are involved in this process.

Our laboratory has shown that transformed cells elaborate extracellular ventral membrane protrusions termed "invadopodia" at the cell-ECM interface (12). These specialized structures exhibit cell surface proteolytic activities that allow metastatic cells to dissolve the surrounding matrix. Furthermore, by utilizing an *in vitro* assay system that consists of growing cells on fluorescence labeled or radiolabeled ECM components that are covalently crosslinked to gelatin film, we can detect the elaboration of invadopodia by human cancer cell lines (15). As a result of this ECM invasion/degradation assay our laboratory identified a highly invasive melanoma cell line, LOX, from over 32 human tumor cell lines (16). This cell line had previously been shown to have a high incidence of lung metastasis after intravenous injection into athymic mice (17). Recently, two additional cell lines were identified, another melanoma line RPMI7951 and a breast carcinoma cell line MDA-MB-436 that exhibited the invasive phenotype.

LOX cells express a 170 kDa membrane-bound gelatinase, mp170 seprase, that has been reported to be localized on invadopodia and whose expression correlates with LOX invasiveness in the *in vitro* ECM degradation/invasion assay (18). It is a homodimer consisting of 97 kDa subunits that are proteolytically inactive(19). Recently, mp170 seprase was classified as a serine protease whose active site is generated upon subunit association (19). Preliminary protein sequence data obtained from 3 internal peptides that were generated by digesting the 97 kDa subunit with the endopeptidase Lys C indicated that mp170 seprase was homologous to fibroblast activation protein α (FAPα) and to dipeptidyl peptidase IV (DPPIV) (19). Fibroblast activation protein α is a 95 kDa type II integral membrane protein of unknown function that is homologous to DPPIV (48% amino acid identity). It is selectively expressed *in vivo* on reactive stromal fibroblasts of carcinomas and healing wounds and on sarcoma tumor tissues; *in vitro* it is expressed on fibroblasts and some tumor cell lines but not on carcinoma cell lines (20,21,22). Dipeptidyl peptidase IV is a multifunctional protein that has wide tissue distribution and is a member of a new subfamily of nonclassical serine hydrolases(23,24,25). Like mp170 seprase its protease activity is dependent on the association of its 110 kDa subunits (26,27).

Purpose of present work

We initially proposed to determine the role of mp170 seprase in the metastasis of breast cancer. The *in vitro* breast carcinoma line MDA-MB-436 which is known to express mp170 seprase would appear to be a good candidate for transfection experiments with sense and antisense cDNA constructs of mp170 seprase. Using the *in vitro* ECM invasion/degradation assay we could monitor the effects of the overexpression and underexpression of this gelatinase on the invasive phenotype of MDA-MB-436 as well as other cell lines (MDA-MB-231 etc.) at various stages of neoplastic development. Therefore, our first priority is to isolate a cDNA clone that encodes the entire open reading frame(ORF) of mp170 seprase.

Methods of approach

The results presented above, namely, the sequence homology of internal peptides, subunit size similarity and the ability of the mp170 seprase and FAPα to associate with DPPIV and form a heteromeric complex (20) suggested that these two proteins may be highly homologous. Thus, oligonucleotide primers based on the FAPα cDNA sequence(20) could be used to synthesize a cDNA probe from LOX mRNA by reverse transcriptase-polymerase chain reaction(RT-PCR) to screen a LOX cDNA library. Confirmation of a putative positive clone(s) would be accomplished by subcloning the cDNA insert in a mammalian expression vector and transfecting COS-7 cells. Identification of mp170 seprase would be accomplished with anti-mp170 seprase mAbs and in a functional assay by performing gelatin zymography on transfected COS-7 cell detergent extracts. As will be described in the Body section of this report we abandoned screening of a cDNA library and utilized RT-PCR to generate a cDNA clone that encodes the 97 kDa subunit of mp170 seprase.

BODY

Screening of LOX cDNA library

In the previous annual report we isolated two putative mp170 seprase clones from a LOX lambda gt11 cDNA library. These clones were isolated using an amplicon (0.8 kb) that was generated by RT-PCR of LOX mRNA using primers that corresponded to the FAPα cDNA sequence [sense: 5'-CCAGCAATGATAGCCTCAA-3' (#1055-1073); antisense: 5'-ACAGACCTTACACTCTGAC-3'(#1863-1845)]. The two putative mp170 seprase clones lambda 50A2 (1.8 kb) and lambda 30B1 (1.4 kb) appeared to overlap each other and encode the entire open reading frame predicted by the FAPα cDNA sequence (2277 bp). This conclusion was based on restriction endonuclease digests of these clones using 9 enzymes and a computer generated restriction map of the FAPα cDNA. However, sequence analysis of both clones revealed that although they exhibited regions of identity with the FAPα cDNA sequence both clones contained unrelated sequence inserts in their putative overlap region. Specifically, lambda 50A2 showed identity with the FAPα cDNA corresponding to nucleotide positions #161 to 1610 (the ORF begins at # 209); it contained an insert at its 3' end of ~250 bp which when translated would cause premature termination of mp170 seprase 8 residues downstream of the insertion point. Likewise, lambda 30B1 which encoded the 3' region of the ORF, showed identity with the FAPα cDNA from nucleotide positions # 1531 to 2523 (termination of the ORF at #2486); however, it contained an insertion of 120 bp between nucleotide positions #1610 and 1611 which would prematurely terminate translation 2 residues downstream from its insertion point. It also contained a deletion of 170 bp between positions # 1658 and 1828 which would terminate translation 9 residues downstream of the deletion. Analysis of the sequences surrounding the regions of insertions and deletions did not indicate that they were exon-intron junctions nor did the inserts appear to be Alu sequences. As a result of these findings and similar findings with other clones from this library we decided to abandon the library screening procedure and attempt to generate a cDNA clone that encoded the complete ORF of mp170 seprase by RT-PCR

Isolation of mp170 seprase cDNA

Using oligonucleotide primers that correspond to the 5' untranslated region (UTR) and the 3' UTR of the FAPα cDNA [sense: 5'-CCACGCTCTGAAGACAGAATT-3' (#161-181); antisense: 5'-TCAGATTCTGATACAGGCT-3' (#2523-2505)] we carried out RT-PCR of LOX total RNA. The resultant ~ 2.4 kb amplicon was subcloned into the mammalian expression vector pCR3.1 (Invitrogen). We transfected COS-7 cells with a recombinant plasmid, pA15, that contained the ~ 2.4 kb insert and also carried out mock transfections with the ligated expression vector, pA11. To determine if this amplicon

encoded mp170 seprase we utilized two monoclonal antibodies (mAbs), D8 and D28, which recognize epitopes on both dimeric mp170 seprase and its 97 kDa subunit (18). Both mAbs stained cells that had been transfected with pA15 but did not specifically stain cells transfected with pA11. In addition, we utilized a class matched negative control mAb(IgG2a) that did not specifically stain cells transfected with pA15. Western blot analysis of detergent extracts of pA15 and pA11 transfected COS-7 cells using mAbs D8 and D28 confirmed the cell staining experiments. Both mAbs detected a band at ~ 170 kDa in pA15 extracts which comigrated with the band detected from LOX extract. No corresponding band was detected in pA11 extracts. Similarly, when mp170 seprase was dissociated by heat into its 97 kDa subunit in the pA15 and LOX detergent extracts it was recognized by mAb D8 but not in the pA11 extracts. Furthermore, in a functional assay to detect proteolytic activity by gelatin zymography (Fig. 1) the pA15 extract gave rise to a gelatinolytic band at ~ 170 kDa that comigrated with the region of lysis produced by the LOX extract. No gelatinolytic band was detected in the mock transfected COS-7 cells. We also confirmed the identity of the gelatinolytic bands observed with the pA15 and LOX extracts by forming mp170 seprase-mAb complexes using the mAbs D8 and D28. Complex formation upshifted the proteolytic activity bands in these extracts but a class matched negative control mAb did not. Thus, we feel that the results from immunostaining of transfected COS-7 cells coupled with Western blot analysis and gelatin zymography of transfected COS-7 cell detergent extracts confirm that pA15 encodes mp170 seprase.

Sequence analysis of pA15 cDNA insert

Both strands of the cDNA were sequenced using sense and antisense oligonucleotide primers that generated overlapping sequence data on each strand. Sequence analysis of the cDNA insert of pA15 revealed an ORF of 2280 bp which encodes a polypeptide of 760 amino acids with a M_r 87,722 (Fig.2). The cDNA sequence predicts a type II integral membrane protein with a short cytoplasmic tail (6 amino acids) followed by a hydrophobic transmembrane domain (20 amino acids) and a relatively large extracellular domain composed of 734 amino acids. There are 5 potential N-glycosylation sites: 4 of the sites are clustered in a membrane proximal region extending from Asn^{49} to Asn^{314} with the fifth site Asn^{679} located in the putative catalytic region (see below). There are 12 cysteine residues: 7 of these residues are clustered in a region that extends from Cys^{305} to Cys^{448}. Located at the carboxyl terminus is a putative catalytic region consisting of ~240 amino acids that extends from Tyr^{520} to Asp^{760}. Within this region is the catalytic triad of residues Ser^{624}, Asp^{702} and His^{734} which are in a nonclassical sequence orientation (23,24,25). The consensus motif Gly-X-Ser-X-Gly which is characteristic of serine proteases is conserved around Ser^{624}.

Sequence comparison of pA15 and FAPα cDNA coding regions

A comparison of the nucleotide sequence of the pA15 cDNA to that for FAPα (20) indicated a difference of 8 base pairs in the ORF of their respective cDNAs (Fig.2). There are 5 base substitutions: 3 give rise to nonconservative amino acid substitutions at residues #207 (Pro to Ala), #229 (Lys to Thr) and #354 (Arg to Thr), respectively. The fourth and fifth are silent substitutions corresponding to nucleotide positions #252 (A to G) and #2124 (A to G), respectively. The remaining difference of 3 bp is due to the insertion of 3 guanine nucleotides at positions #1876 or 1877, 1879 or 1880 and 2010 in the pA15 cDNA. The nucleotide sequence from nucleotide #1876-G to #2010-G encodes a contiguous sequence of 45 amino acids extending from Gly^{626} to Lys^{670} in the putative catalytic region. This sequence overlaps the serine protease conserved sequence motif Gly-X-Ser-X-Gly which is not conserved in FAPα. Thus the difference of 8 bp between the mp170 and FAPα cDNAs gives rise to a total difference of 48 amino acids in their deduced polypeptide sequences or an amino acid identity of ~ 94%.

We reported last year that we had detected the presence of mp170seprase/FAPα mRNA in the breast carcinoma cell line MDA-MB-436 using FAPα sense and antisense primers by RT-PCR. After determining the sequence of pA15 we carried out RT-PCR on MDA-MB-436 total RNA with the same sense and antisense primers used to generate pA15. Preliminary sequence analysis (1 strand) of cDNA clones from MDA-MB-436 found a difference of 4 bp with pA15 in the coding region: two base substitutions give rise to nonconservative amino acid substitutions at position #133 (Tyr to His) and position #279 (Glu to Gly). The remaining two substitutions at nucleotide positions #252 (G to A) and #2124 (G to A) are silent. Importantly, the insertion of 3 G nucleotides in the sequence encoding the catalytic region of pA15 is confirmed in MDA-MB-436. This result was also observed for mp170 seprase in the invasive melanoma cell line RPMI7951.

CONCLUSIONS

Isolation and identification of a cDNA clone (pA15) that encodes mp170 seprase confirms the previously obtained peptide sequence data from the its 97 kDa subunit (19). Namely, that mp170 seprase exhibits highest homology with human FAPα. There is also a striking sequence identity with the ectoenzyme DPPIV (28,29,30). The amino acid identity between mp170 seprase and DPPIV is 52% but increases to 68% in the catalytic region. The high extent of sequence identity between the pA15 and FAPα cDNAs indicates that either both encode the same protein or virtually identical proteins. The significance of the 3 nonconservative amino acid substitutions remains to be determined. However, the 3 guanine nucleotide insertions in the pA15 cDNA result in a divergence of the amino acid sequence (45 contiguous residues) in the putative catalytic region of this protein (Fig.2). Importantly, the consensus sequence motif Gly-X-Ser-X-Gly which is identical in mp170 seprase and the related mammalian protease DPPIV (Gly-Trp-Ser-Tyr-Gly; see below) is not conserved in FAPα (Gly-Trp-Ser-Tyr-Glu). The substitution of Gly^{626} with Glu in FAPα could be significant since it has been reported that substitution of this Gly residue in rat DPPIV results in complete loss of proteolytic activity (31) and no proteolytic activity has yet been ascribed to FAPα. Thus if the divergence in the nucleotide sequence encoding this region in FAPα is not an artifact, then there may be important differences in the biological activities of these two proteins. Also, multiple nonproteolytic functions have been ascribed to DPPIV (32-35). For example, it has been reported to bind the ECM components fibronectin and collagen (32,33). It is interesting to speculate whether these DPPIV structurally related proteins, mp170 seprase and FAPα, may function in roles other than or in addition to integral membrane proteases. Indeed, the fact that mp170 seprase is expressed on invasive melanoma cell lines (16,17,18) while FAPα can be expressed on "reactive" fibroblasts of carcinomas (21,22) could mean that these very similar proteins may have different roles when they are expressed on cells with different metastatic potentials.

Our next priority will be to transfect human breast carcinoma cell lines such as MDA-MB 436 or MDA-MB-231(negative for mp170 seprase by RT-PCR analysis) etc. as well as normal epithelial cell lines with sense and/or antisense constructs of mp170 seprase. We will use constructs encoding DPPIV that are generated by RT-PCR and subcloned in the pCR3.1 vector in sense and antisense orientations as one of our controls. In addition, since it is known that mp170 seprase and FAPα (20) form heteromeric complexes with DPPIV, we will also do cotransfections with constructs for these homologous proteins. It should be noted that their proteolytic substrate specificities are distinct (19).We will then attempt to detect possible phenotypic changes in our transfected cell lines as a result of increased expression or inhibition of expression of mp170 seprase using the *in vitro* invasion/degradation assay etc. If phenotypic changes are detected we will begin to pursue the underlying biochemical and cell biological mechanisms that are involved.

REFERENCES

1. Mignatti, P. and Rifkin, D.B. (1993) *Physiol. Rev.* **73,** 161-195
2. Stetler-Stevenson, W.G., Aznavoorian, S., and Liotta, L.A. (1993) *Annu. Rev. Cell Biol.* **9,** 541-573
3. Quax, P.H.A., Van Muijen, G.N.P., Weening-Verhoeff, E.J.D., Lund, L.R., Dano, K., Ruiter, D.J., and Verheijen, J.H. (1991) *J. Cell Biol.* **115,** 191-199
4. Hagia, Y., Fukao, H., Veshima, S., Inufusa, H., Izaki, S., Kamiishi, H., Okada, K., and Matsuo, O. (1992) *Thromb. Res.* **65,** 449-456
5. Sloane, B.F. (1990) *Semin Cancer Biol.* **1,** 137-152
6. Buck, M.R., Karustis, D.G., Day, N.A., Honn, K.V., and Sloane, B.F. (1992) *Biochem. J.* **282,** 273-278
7. Templeton, N.S., Stetler-Stevenson, W.G. (1991) *Cancer Res.* **51,** 6190-6193
8. Tryggvason, K., Hoyhta, M., and Pyke, C. (1993) *Breast Cancer Res. Treat.* **24,** 209-218
9. Sato, H., Kida, Y., Mai, M., Endo, Y., Sasaki, T., Tanaka, J., and Seiki, M. (1992) *Oncogene* **7,** 77-83
10. Rochefort, H. (1992) *Eur. J. Cancer* **28A,** 1780-1783
11. Rochefort, H. (1990) *Semin. Cancer Biol.* **1,** 153-160
12. Chen, W.-T. (1996) *Enzyme Protein* **49,** 59-71
13. Pollanen, J., Stephens, R.W., and Vaheri, A. (1991) *Adv. Cancer Res.* **57,** 273-328
14. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) *Nature* **370,** 61-65
15. Chen, W.-T., Lee, C.C., Goldstein, L., Bernier, S., Liu, C.Y., Yeh, Y., Monsky, W.L., Kelly, T., Dai, M., Zhou, J.Y., Mueller, S.C. (1994) *Breast Cancer Res. Treat.* **31,** 217-226
16. Aoyama, A. and Chen, W.-T. (1990) *Proc. Natl. Acad. Sci. USA*

    87, 8296-8300
17. Fodstad, O., Kjonniksen, I., Aamdal, S., Nesland, J.M., Boyd, M.R., and Pihl, A. (1988) *Cancer Res.* **48,** 4382-4388
18. Monsky, W.L., Lin, C.-Y., Aoyama, A., Kelly, T., Mueller, S.C., Akiyama, S.K., and Chen, W.-T. (1994) *Cancer Res.* **54,** 5702-5710

19. Piñeiro-Sánchez, M.L., . Goldstein, L.A., Dodt, J., Howard, L., Yeh, Y., and Chen, W.-T. (1996) *J. Biol. Chem.* Submitted.

20. Scanlan, M.J., Mohan Raj, B.K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M.P., Healy, J.H., Old, L.J., and Rettig, W.J. (1994) *Proc. Natl. Acad. Sci. USA* **91,** 5657-5661

21. Rettig, W.J., Garin-Chesa, P., Beresford, H.R., Oettgen, H.F., Melamed, M.R., and Old, L.J. (1988) *Proc. Natl. Acad. Sci. USA* **85,** 3110-3114

22. Garin-Chesa, P., Old, L.,J., and Rettig, W.J. (1990) *Proc. Natl. Acad. Sci. USA* **87,** 7235-7239

23. Marguet, D., Bernard, A.M., Vivier, I., Darmoul, D., Naquet, P., and Pierres, M. (1992) *J. Biol. Chem.* **267,** 2200-2208

24. David, F., Bernard, A.M., Pierres, M., and Marquet, D. (1993) *J. Biol. Chem.* **268,** 17247-17252

25. Polgar, L. (1992) *FEBS Lett.* **311,** 281-284

26. Puschel, G., Mentlein, R., and Heymann, E. (1982) *Eur. J. Biochem.* **126,** 359-365

27. Walborg, E.F.J., Tsuchida, S., Weeden, D.S., Thomas, M.W., Barrick, A., McEntire, K.D., Allison, J.P., and Hixson, D.C. (1985) *Experimental Cell Research* **158,** 509-518

28. Misumi, Y., Hayashi, Y., Arakawa, F., and Ikehara, Y. (1992) *Biochim. Biophys. Acta* **1131,** 333-336

29. Tanaka, T., Camerini, D., Seed, B., Torimoto, Y., Dang, N.H., Kameoka, J., Dahlberg, H.N., Schlossman, S.F., and Morimoto, C. (1992) *J. Immunol.* **149,** 481-486

30. Darmoul, D., Lacasa, M., Baricault, L., Marguet, D., Sapin, C., Trotot, P., Barbat, A., and Trugnan, G. (1992) *J. Biol. Chem.* **267,** 4824-4833

31. Ogata, S., Misumi, Y., Tsuji, E., Takami, N., Oda, K., and Ikehara, Y. (1992) *Biochemistry* **31,** 2582-2587

32. Piazza, G.A., Callanan, H.M., Mowery, J., and Hixson, D.C. (1989) *Biochem. J.* **262,** 327-334

33. Dang, N.H., Torimoto, Y., Sugita, K., Daley, J.F., Schow, P., Prado, C., Schlossman, S.F., and Morimoto, C. (1990) *J. Immunol.* **145,** 3963-3971

34. Johnson, R.C., Zhu, D., Augustin-Voss, H.G., and Pauli, B.U. (1993) *J. Cell Biol* **121,** 1423-1432

35. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S.F., and Morimoto, C. (1993) *Science* **261,** 466-469

APPENDIX

Figure Legends

Fig. 1. **pA15 encodes functional mp170 seprase.**

Detergent extracts from mock and pA15 transfected COS-7 cells and WGA purified LOX cell extract (19) were assayed for proteolytic activity by gelatin zymography (*Lanes* 1-9). *Lanes* 5-9 demonstrate that anti-mp170 seprase mAbs specifically form complexes with the gelatinolytic activity. *Lane* 1, mock transfected (pA11) COS-7 cells (20 μg). *Lane* 2, mock transfected cells that were panned with anti-mp170 mAb D28 (<1 μg). *Lane* 3, pA15 transfected COS-7 cells panned with D28 (~5 μg). *Lane* 4, LOX cell detergent extract purified by WGA chromatography (~30 μg). *Lane* 5, same as *lane* 4 + 5 μl of B5 - a class matched (IgG2a) negative control mAb hybridoma supernatant. *Lane* 6, same as *lane* 4 + 5 μl of anti-mp170 seprase D8. *Lane* 7, same as *lane* 4 + 5 μl of anti-mp170 seprase D28. *Lane* 8, same as *lane* 3 + 5 μl D8. *Lane* 9, same as *lane* 3 + 5 μl of D28. Hybridoma supernatants were incubated with extracts for 2 h at 4 °C.

Fig. 2. **Nucleotide and deduced amino acid sequences for the coding region of pA15.**

Nucleotide and amino acid sequence numbers are shown to the right. The putative transmembrane region is represented in bold characters. Potential N-glycosylation sites are shown as bold *italicized* characters. Nucleotide substitutions and insertions relative to the FAPα cDNA sequence are underlined. Amino acid substitutions relative to the deduced amino acid sequence of the FAPα cDNA are represented by underlined characters. The putative catalytic triad of mp170 seprase (Ser^{624}, Asp^{702}, His^{734}) is represented by bold underlined characters.

Figure 1.



Figure 2.

```
ATG AAG ACT TGG GTA AAA ATC GTA TTT GGA GTT GCC ACC TCT GCT GTG CTT GCC TTA TTG GTG ATG TGC ATT GTC    75
M   K   T   W   V   K   I   V   F   G   V   A   T   S   A   V   L   A   L   L   V   M   C   I   V      25
TTA CGC CCT TCA AGA GTT CAT AAC TCT GAA GAA AAT ACA ATG AGA GCA CTC ACA CTG AAG GAT ATT TTA AAT GGA   150
L   R   P   S   R   V   H   N   S   E   E   N   T   M   R   A   L   T   L   K   D   I   L   N   G      50
ACA TTT TCT TAT AAA ACA TTT TTT CCA AAC TGG ATT TCA GGA CAA GAA TAT CTT CAT CAA TCT GCA GAT AAC AAT   225
T   F   S   Y   K   T   F   F   P   N   W   I   S   G   Q   E   Y   L   H   Q   S   A   D   N   N      75
ATA GTA CTT TAT AAT ATT GAA ACA GGG CAA TCA TAT ACC ATT TTG AGT AAT AGA ACC ATG AAA AGT GTG AAT GCT   300
I   V   L   Y   N   I   E   T   G   Q   S   Y   T   I   L   S   N   R   T   M   K   S   V   N   A     100
TCA AAT TAC GGC TTA TCA CCT GAT CGG CAA TTT GTA TAT CTA GAA AGT GAT TAT TCA AAG CTT TGG AGA TAC TCT   375
S   N   Y   G   L   S   P   D   R   Q   F   V   Y   L   E   S   D   Y   S   K   L   W   R   Y   S     125
TAC ACA GCA ACA TAT TAC ATC TAT GAC CTT AGC AAT GGA GAA TTT GTA AGA GGA AAT GAG CTT CCT CGT CCA ATT   450
Y   T   A   T   Y   Y   I   Y   D   L   S   N   G   E   F   V   R   G   N   E   L   P   R   P   I     150
CAG TAT TTA TGC TGG TCG CCT GTT GGG AGT AAA TTA GCA TAT GTC TAT CAA AAC AAT ATC TAT TTG AAA CAA AGA   525
Q   Y   L   C   W   S   P   V   G   S   K   L   A   Y   V   Y   Q   N   N   I   Y   L   K   Q   R     175
CCA GGA GAT CCA CCT TTT CAA ATA ACA TTT AAT GGA AGA GAA AAT AAA ATA TTT AAT GGA ATC CCA GAC TGG GTT   600
P   G   D   P   P   F   Q   I   T   F   N   G   R   E   N   K   I   F   N   G   I   P   D   W   V     200
TAT GAA GAG GAA ATG CTT GCT ACA AAA TAT GCT CTC TGG TGG TCT CCT AAT GGA AAA TTT TTG GCA TAT GCG GAA   675
Y   E   E   E   M   L   A   T   K   Y   A   L   W   W   S   P   N   G   K   F   L   A   Y   A   E     225
TTT AAT GAT ACG GAT ATA CCA GTT ATT GCC TAT TCC TAT TAT GGC GAT GAA CAA TAT CCT AGA ACA ATA AAT ATT   750
F   N   D   T   D   I   P   V   I   A   Y   S   Y   Y   G   D   E   Q   Y   P   R   T   I   N   I     250
CCA TAC CCA AAG GCT GGA GCT AAG AAT CCC GTT GTT CGG ATA TTT ATT ATC GAT ACC ACT TAC CCT GCG TAT GTA   825
P   Y   P   K   A   G   A   K   N   P   V   V   R   I   F   I   I   D   T   T   Y   P   A   Y   V     275
GGT CCC CAG GAA GTG CCT GTT CCA GCA ATG ATA GCC TCA AGT GAT TAT TAT TTC AGT TGG CTC ACG TGG GTT ACT   900
G   P   Q   E   V   P   V   P   A   M   I   A   S   S   D   Y   Y   F   S   W   L   T   W   V   T     300
GAT GAA CGA GTA TGT TTG CAG TGG CTA AAA AGA GTC CAG AAT GTT TCG GTC CTG TCT ATA TGT GAC TTC AGG GAA   975
D   E   R   V   C   L   Q   W   L   K   R   V   Q   N   V   S   V   L   S   I   C   D   F   R   E     325
GAC TGG CAG ACA TGG GAT TGT CCA AAG ACC CAG GAG CAT ATA GAA GAA AGC AGA ACT GGA TGG GCT GGT GGA TTC  1050
D   W   Q   T   W   D   C   P   K   T   Q   E   H   I   E   E   S   R   T   G   W   A   G   G   F     350
TTT GTT TCA ACA CCA GTT TTC AGC TAT GAT GCC ATT TCG TAC TAC AAA ATA TTT AGT GAC AAG GAT GGC TAC AAA  1125
F   V   S   T   P   V   F   S   Y   D   A   I   S   Y   Y   K   I   F   S   D   K   D   G   Y   K     375
CAT ATT CAC TAT ATC AAA GAC ACT GTG GAA AAT GCT ATT CAA ATT ACA AGT GGC AAG TGG GAG GCC ATA AAT ATA  1200
H   I   H   Y   I   K   D   T   V   E   N   A   I   Q   I   T   S   G   K   W   E   A   I   N   I     400
TTC AGA GTA ACA CAG GAT TCA CTG TTT TAT TCT AGC AAT GAA TTT GAA GAA TAC CCT GGA AGA AGA AAC ATC TAC  1275
F   R   V   T   Q   D   S   L   F   Y   S   S   N   E   F   E   E   Y   P   G   R   R   N   I   Y     425
AGA ATT AGC ATT GGA AGC TAT CCT CCA AGC AAG AAG TGT GTT ACT TGC CAT CTA AGG AAA GAA AGG TGC CAA TAT  1350
R   I   S   I   G   S   Y   P   P   S   K   K   C   V   T   C   H   L   R   K   E   R   C   Q   Y     450
TAC ACA GCA AGT TTC AGC GAC TAC GCC AAG TAC TAT GCA CTT GTC TGC TAC GGC CCA GGC ATC CCC ATT TCC ACC  1425
Y   T   A   S   F   S   D   Y   A   K   Y   Y   A   L   V   C   Y   G   P   G   I   P   I   S   T     475
CTT CAT GAT GGA CGC ACT GAT CAA GAA ATT AAA ATC CTG GAA GAA AAC AAG GAA TTG GAA AAT GCT TTG AAA AAT  1500
L   H   D   G   R   T   D   Q   E   I   K   I   L   E   E   N   K   E   L   E   N   A   L   K   N     500
ATC CAG CTG CCT AAA GAG GAA ATT AAG AAA CTT GAA GTA GAT GAA ATT ACT TTA TGG TAC AAG ATG ATT CTT CCT  1575
I   Q   L   P   K   E   E   I   K   K   L   E   V   D   E   I   T   L   W   Y   K   M   I   L   P     525
CCT CAA TTT GAC AGA TCA AAG AAG TAT CCC TTG CTA ATT CAA GTG TAT GGT GGT CCC TGC AGT CAG AGT GTA AGG  1650
P   Q   F   D   R   S   K   K   Y   P   L   L   I   Q   V   Y   G   G   P   C   S   Q   S   V   R     550
TCT GTA TTT GCT GTT AAT TGG ATA TCT TAT CTT GCA AGT AAG GAA GGG ATG GTC ATT GCC TTG GTG GAT GGT CGA  1725
S   V   F   A   V   N   W   I   S   Y   L   A   S   K   E   G   M   V   I   A   L   V   D   G   R     575
GGA ACA GCT TTC CAA GGT GAC AAA CTC CTC TAT GCA GTG TAT CGA AAG CTG GGT GTT TAT GAA GTT GAA GAC CAG  1800
G   T   A   F   Q   G   D   K   L   L   Y   A   V   Y   R   K   L   G   V   Y   E   V   E   D   Q     600
ATT ACA GCT GTC AGA AAA TTC ATA GAA ATG GGT TTC ATT GAT GAA AAA AGA ATA GCC ATA TGG GGC TGG TCC TAT  1875
I   T   A   V   R   K   F   I   E   M   G   F   I   D   E   K   R   I   A   I   W   G   W   S   Y     625
GGA GGA TAC GTT TCA TCA CTG GCC CTT GCA TCT GGA ACT GGT CTT TTC AAA TGT GGT ATA GCA GTG GCT CCA GTC  1950
G   G   Y   V   S   S   L   A   L   A   S   G   T   G   L   F   K   C   G   I   A   V   A   P   V     650
TCC AGC TGG GAA TAT TAC GCG TCT GTC TAC ACA GAG AGA TTC ATG GGT CTC CCA ACA AAG GAT GAT AAT CTT GAG  2025
S   S   W   E   Y   Y   A   S   V   Y   T   E   R   F   M   G   L   P   T   K   D   D   N   L   E     675
CAC TAT AAG AAT TCA ACT GTG ATG GCA AGA GCA GAA TAT TTC AGA AAT GTA GAC TAT CTT CTC ATC CAC GGA ACA  2100
H   Y   K   N   S   T   V   M   A   R   A   E   Y   F   R   N   V   D   Y   L   L   I   H   G   T     700
GCA GAT GAT AAT GTG CAC TTT CAG AAC TCA GCA CAG ATT GCT AAA GCT CTG GTT AAT GCA CAA GTG GAT TTC CAG  2175
A   D   D   N   V   H   F   Q   N   S   A   Q   I   A   K   A   L   V   N   A   Q   V   D   F   Q     725
GCA ATG TGG TAC TCT GAC CAG AAC CAC GGC TTA TCC GGC CTG TCC ACG AAC CAC TTA TAC ACC CAC ATG ACC CAC  2250
A   M   W   Y   S   D   Q   N   H   G   L   S   G   L   S   T   N   H   L   Y   T   H   M   T   H     750
TTC CTA AAG CAG TGT TTC TCT TTG TCA GAC TAA                                                          2283
F   L   K   Q   C   F   S   L   S   D                                                                760
```